{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:53:59Z","timestamp":1791975239314,"version":"4.4.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Identification of modulators of the immune response with inhibitory properties that could be susceptible for therapeutic intervention is a key goal in cancer research. An example is the human leukocyte antigen G (HLA-G), a nonclassical major histocompatibility complex (MHC) class I molecule, involved in cancer progression. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this article we performed a systematic review and meta-analysis on the association between HLA-G expression and outcome in solid tumors. This study was performed in accordance with PRISMA guidelines and registered in PROSPERO.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 25 studies met the inclusion criteria. These studies comprised data from 4871 patients reporting overall survival (OS), and 961 patients, reporting disease free survival (DFS). HLA-G expression was associated with worse OS (HR 2.09, 95% CI = 1.67 to 2.63; P &amp;lt; .001), that was higher in gastric (HR = 3.40; 95% CI = 1.64 to 7.03), pancreatic (HR = 1.72; 95% CI = 0.79 to 3.74) and colorectal (HR = 1.55; 95% CI = 1.16 to 2.07) cancer. No significant differences were observed between the most commonly utilized antibody (4H84) and other methods of detection. HLA-G expression was associated with DFS which approached but did not meet statistical significance. <\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In summary, we describe the first meta-analysis associating HLA-G expression and worse survival in a variety of solid tumors. <\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:uri>, identifier CRD42022311973.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1165813","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T05:08:31Z","timestamp":1684386511000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Jorge","family":"Bartolome","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consolacion","family":"Molto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier David","family":"Benitez-Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Fernandez-Hinojal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aranzazu","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Perez-Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhenil","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris","family":"Tamimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ocana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.592010","article-title":"Roles of HLA-G in the maternal-fetal immune microenvironment","volume":"11","author":"Xu","year":"2020","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1006\/scbi.1998.0103","article-title":"The immunotolerance role of HLA-G","volume":"9","author":"Rouas-Freiss","year":"1999","journal-title":"Semin Cancer Biol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0065-2776(03)81006-4","article-title":"HLA-G molecules: from maternal-fetal tolerance to tissue acceptance","volume":"81","author":"Carosella","year":"2003","journal-title":"Adv Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0097","article-title":"HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism","volume":"65","author":"Rouas-Freiss","year":"2005","journal-title":"Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.2326636","article-title":"A class I antigen, HLA-G, expressed in human trophoblasts","volume":"248","author":"Kovats","year":"1990","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.8.4510","article-title":"HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance","volume":"95","author":"Paul","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.698677","article-title":"HLA-G\/ILTs targeted solid cancer immunotherapy: opportunities and challenges","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/bs.ai.2015.04.001","article-title":"HLA-G: an immune checkpoint molecule","volume":"127","author":"Carosella","year":"2015","journal-title":"Adv Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2012.07.041","article-title":"Human leukocyte antigen-G (HLA-G) expression in cervical cancer lesions is associated with disease progression","volume":"73","author":"Li","year":"2012","journal-title":"Hum Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1309\/JNCW1QLDFB6AM9WE","article-title":"Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma","volume":"128","author":"Yie","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1158\/1535-7163.MCT-22-0351","article-title":"Inhibition of LILRB2 by a novel blocking antibody designed to reprogram immunosuppressive macrophages to drive T cell activation in tumors","volume":"10","author":"Umiker","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004859","article-title":"BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression","volume":"10","author":"Mandel","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2015.00083","article-title":"Human leukocyte antigen-G (HLA-G) expression in cancers: roles in immune evasion, metastasis and target for therapy","volume":"21","author":"Lin","year":"2015","journal-title":"Mol Med"},{"key":"B14","article-title":"Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition","volume-title":"Chichester (UK): John Wiley & Sons","author":"Higgins","year":"2019"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"B16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jrsm.1211","article-title":"Neither fixed nor random: weighted least squares meta-regression","volume":"8","author":"Stanley","year":"2017","journal-title":"Res Synth Methods"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(90)90093-5","article-title":"Indexes and boundaries for \u201cquantitative significance\u201d in statistical decisions","volume":"43","author":"Burnand","year":"1990","journal-title":"J Clin Epidemiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12885-022-09169-0","article-title":"An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer","volume":"22","author":"Bennedsen","year":"2022","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/tan.13536","article-title":"HLA-G, HLA-e, and IDO overexpression predicts a worse survival of Tunisian patients with vulvar squamous cell carcinoma","volume":"94","author":"Boujelbene","year":"2019","journal-title":"HLA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0463","article-title":"Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection","volume":"15","author":"Cai","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.01951.x","article-title":"Human leukocyte antigen-G is closely associated with tumor immune escape in gastric cancer by increasing local regulatory T cells","volume":"102","author":"Du","year":"2011","journal-title":"Cancer Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-20-2211","article-title":"Plasma soluble human leukocyte antigen G predicts the long-term prognosis in patients with colorectal cancer","volume":"9","author":"Jiao","year":"2020","journal-title":"Transl Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14514","article-title":"Expression of classical human leukocyte antigen class I antigens, HLA-e and HLA-G, is adversely prognostic in pancreatic cancer patients","volume":"111","author":"Hiraoka","year":"2020","journal-title":"Cancer Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/1933719109342131","article-title":"Correlation of human leukocyte antigen-G (HLA-G) expression and disease progression in epithelial ovarian cancer","volume":"16","author":"Jung","year":"2009","journal-title":"Reprod Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2016.01.002","article-title":"The prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patients","volume":"77","author":"K\u00f6nig","year":"2016","journal-title":"Hum Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16457","article-title":"Importance of the plasma soluble HLA-G levels for prognostic stratification with traditional prognosticators in colorectal cancer","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25807","article-title":"Human leukocyte antigen-G expression is associated with a poor prognosis in patients with esophageal squamous cell carcinoma","volume":"129","author":"Lin","year":"2011","journal-title":"Int J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-018-2379-0","article-title":"HLA-G expression in gastric carcinoma: clinicopathological correlations and prognostic impact","volume":"473","author":"Murdaca","year":"2018","journal-title":"Virchows Arch"},{"key":"B29","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/1471-2407-14-486","article-title":"Prognostic value of HLA class I, HLA-e, HLA-G and tregs in rectal cancer: a retrospective cohort study","volume":"14","author":"Reimers","year":"2014","journal-title":"BMC Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.5812\/ijcm.9346","article-title":"Clinical value of human leucocyte antigen G (HLA-G) expression in the prognosis of colorectal cancer","volume":"10","author":"Samadi","year":"2017","journal-title":"Int J Cancer Manage"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2010.02.015","article-title":"Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients","volume":"71","author":"Sch\u00fctt","year":"2010","journal-title":"Hum Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30760","article-title":"Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer","volume":"141","author":"Sideras","year":"2017","journal-title":"Int J Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1159\/000485819","article-title":"Human leukocyte antigen-G inhibits the anti-tumor effect of natural killer cells via immunoglobulin-like transcript 2 in gastric cancer","volume":"44","author":"Wan","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.7150\/jca.29655","article-title":"Diagnostic and prognostic biomarkers of human leukocyte antigen complex for hepatitis b virus-related hepatocellular carcinoma","volume":"10","author":"Wang","year":"2019","journal-title":"J Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2174\/1566524015666150401102218","article-title":"High expression of human leukocyte antigen-G is associated with a poor prognosis in patients with PDAC","volume":"15","author":"Xu","year":"2015","journal-title":"Curr Mol Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800751","article-title":"Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer","volume":"20","author":"Ye","year":"2007","journal-title":"Mod Pathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9464-y","article-title":"Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma","volume":"14","author":"Yie","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22487","article-title":"Predictive value of different proportion of lesion HLA-G expression in colorectal cancer","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2014.10.003","article-title":"Predictive value of HLA-G and HLA-e in the prognosis of colorectal cancer patients","volume":"293","author":"Guo","year":"2015","journal-title":"Cell Immunol"},{"key":"B40","article-title":"HLA-G impairs host immune response and predicts poor prognosis in pancreatic cancer","volume":"7","author":"Zhou","year":"2015","journal-title":"Am J Transl Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"RELATIVITY-047 investigators. \u201cRelatlimab and nivolumab versus nivolumab in untreated advanced melanoma\u201d","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02164","article-title":"Heterogeneity of HLA-G expression in cancers: facing the challenges","volume":"9","author":"Lin","year":"2018","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0764","article-title":"CD8+PD-1-ILT2+ T cells are an intratumoral cytotoxic population selectively inhibited by the immune-checkpoint HLA-G","volume":"7","author":"Dumont","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02530-x","article-title":"Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets","volume":"69","author":"Tronik-Le Roux","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.642902","article-title":"Prognostic and clinicopathological value of human leukocyte antigen G in gastrointestinal cancers: a meta-analysis","volume":"11","author":"Peng","year":"2021","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.995498","article-title":"Exploring glioblastoma stem cell heterogeneity: immune microenvironment modulation and therapeutic opportunities","volume":"12","author":"Johnson","year":"2022","journal-title":"Front Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2022.08.005","article-title":"Mechanisms of PDAC subtype heterogeneity and therapy response","volume":"8","author":"Espinet","year":"2022","journal-title":"Trends Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2020.1869732","article-title":"HLA-G expression in melanomas","volume":"40","author":"Marletta","year":"2021","journal-title":"Int Rev Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23815","article-title":"T Cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G","volume":"9","author":"Spurny","year":"2017","journal-title":"Oncotarget"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1158\/1078-0432.CCR-21-2160","article-title":"First-in-Class anti-immunoglobulin-like transcript 4 myeloid-specific antibody MK-4830 abrogates a PD-1 resistance mechanism in patients with advanced solid tumors\u201d","volume":"28","author":"Siu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0041","article-title":"Innate immune checkpoint inhibitors: the next breakthrough in medical oncology","volume":"20","author":"Lentz","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B53","unstructured":"Pembrolizumab with chemotherapy and MK-4830 for treating participants with ovarian cancer (MK-4830-002)2022"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1165813\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T05:08:41Z","timestamp":1684386521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1165813\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2023.1165813"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1165813","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"article-number":"1165813"}}